portfolio divers assay develop posit
come pandem rais pt
maintain buy rate rais pt
previous follow result lot like result
even midst suspend guidanc near-term revenu risk move
rapidli develop assay aptima test expect launch next
week signific scale assays/week late may base panther system
management see potenti opportun could prove conserv
viru drag offset declin elect busi unit separ segment
perform februari track better expect organ growth
double-digit growth seen molecular european sale
us surgic management took step shore balanc sheet
preserv cash reduc expens taken togeth assum covid
erad next month opportun emerg enviabl
posit strong underli busi momentum stabil busi unit
combin increment diagnost revenu opportun acceler
revenu growth valuat share move rapidli higher even revenue
growth ep estim near term come look
month think investor becom construct share given
portfolio divers abil remain essenti pandem
launch assay core panther system signific tailwind
announc new aptima assay run core panther system
featur faster throughput far wider instal base vs fusion
ww expect place research-us assay next week
produc assay per week come month follow fda eua applic
next week ce mark approv late may importantli aptima assay
requir sampl prepar commerci reagent reduc relianc raw
materi use multi test swab collect kit allevi depend
common collect transport media overal assay drive higher
util per already-plac system acceler ww instal
test week contribut us-bas panther management see
opportun increment sale assum viru drag
beyond revenu estim could prove low molecular
increment note busi despit guidanc suspens even
suspend guidanc management provid increment color april
trend recoveri assumpt specif within breast skelet health
expect sale y/i recur servic revenu
buoy otherwise-steep decline/long recoveri capit sale gyn-surg
demand drop late march elect procedur postpon management
expect sale y/i believ busi improv clinic
need hospit desir shore financ dx benefit germani
decis adopt co-test cervic cancer screen continu strong
uptak viral load assay africa howev women health test sale fell
significantli routine-screen put hold management expect sale
y/i exclud sale covid assay even viral load test off-set
neg impact
factset btig estim compani
document million except per share amount
valuat rate buy pt base estim
month ep estim risk discuss
believ improv busi overal manag focu core busi aesthet
divestitur believ investor abl home combin reason valuat stabl busi
opportun upsid management acceler core growth long term view intern growth d/new product
launch margin expans consist capit alloc reason
base case assum revenu adj ep
compar pre-covid guidanc revenu
adj ep
upsid current base case would assum area breast health
diagnost gyn surgic grow faster assum think
like opportun higher expect growth within molecular
diagnost segment covid test breast health continu remain
downsid would come increas competit gyn surgic slower growth
area cytolog breast health
make sell product
gyn surgic skelet health
product selenia dimens
diagnost assay panther system
thinprep
report result total revenu y/i line pre-announce result constant-
currenc basi revenu fell y/i organ revenu grew y/i geographi revenu contribut
us europ asia-pacif rest world
segment report breast health revenu y/i consensu pre-covid estim
y/i y/i respect breast imag intervent breast solut revenu came
y/i y/i respect compar pre-covid estim y/i
y/i respect
diagnost revenu came y/i consensu pre-covid estim y/i
y/i respect diagnost revenu ex-blood came y/i within diagnost cytolog
 perinat molecular diagnost revenu came y/i y/i compar
pre-covid estim y/i y/i respect
gyn surgic skelet revenu came y/i y/i compar
consensu pre-covid estim y/i y/i
 adj gross margin pre-covid estim percentag revenu sg
came compar pre-covid estim respect overal adj ep came
consensu pre-covid estim better adjust estim
interest incom
btig estim compani file
made follow chang estim
revenu mix assum april trend management allud within segment carri forward entir
lower pre-pandem estim within breast dx gyn-surg respect
off-set dx busi portion increment revenu opportun expect captur
difficult defin demand test point think number could prove conserv
 lower gm estim beyond lower revenu growth weigh remov
oper expens base management guidanc expect expens pick back
btig estim compani file
btig cover compani mention report
appendix analyst certif import disclosur
